Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2022-05-09 Earnings Release
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer
Earnings Release Classification · 100% confidence The document is an announcement from Nykode Therapeutics detailing positive interim results from a Phase 2 clinical trial (VB C-02) for their drug VB10.16 in treating cervical cancer. It provides efficacy data (ORR, DCR), safety information, quotes from management and investigators, and announces a webcast presentation of these results. This content structure—announcing clinical trial results and providing key data highlights immediately—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it is not a full, comprehensive periodic report (like 10-K or IR), and it focuses on immediate financial/operational news (clinical trial success), 'ER' (Earnings Release) is the closest fit among the options for a major, immediate operational update, even though it's a clinical update rather than traditional quarterly earnings. However, given the specific focus on clinical trial data and the announcement of a webcast to discuss these results, it strongly aligns with the type of press release often categorized as an 'ER' or a general 'RNS' (Regulatory Filing). Since the document is substantial (over 10,000 characters) and contains the full details of the announcement, it is the report itself, not just a notice of publication (RPA). Between ER and RNS, ER is often used for major operational/clinical breakthroughs announced via press release. Given the context of a clinical trial update, 'RNS' (Regulatory Filings/General Announcement) is a safer, broader classification if 'ER' is strictly reserved for financial earnings, but 'ER' often encompasses major operational news releases in practice. Given the high significance of Phase 2 interim results, I will classify it as an 'ER' as it functions as the primary release of new performance data, or 'RNS' as a general regulatory announcement. Since it is a press release announcing clinical data, 'RNS' is the most appropriate general category for non-standard reports, but 'ER' captures the 'release of results' nature. I will lean towards 'ER' as it is a direct release of performance metrics, similar to how earnings are released. Q1 2022
2022-05-09 English
Nykode Therapeutics – Invitation to Capital Markets Day in Oslo on May 12, 2022
Report Publication Announcement Classification · 99% confidence The document is an invitation and announcement for a 'Capital Markets Day' event scheduled for May 12, 2022. It details the agenda (pipeline overview, technology deep dive, capital market strategy including potential uplisting) and logistics (webcast, physical attendance). This type of event, focused on providing detailed strategic and financial updates to investors, aligns best with an Investor Presentation (IP) or a general corporate update. Since it is an invitation to an event where presentations will be given, and it is not a formal regulatory filing like a 10-K or an ER, 'Investor Presentation' (IP) is the most appropriate classification for the content being presented at the event, even though this specific document is the invitation itself. It is not a Report Publication Announcement (RPA) because it is announcing an event, not the publication of a pre-existing formal report like an Annual Report or Interim Report.
2022-05-06 Norwegian
Nykode Therapeutics – Invitation to Capital Markets Day in Oslo on May 12, 2022
Report Publication Announcement Classification · 99% confidence The document is an explicit invitation and announcement for a 'Capital Markets Day' scheduled for May 12, 2022. It details the agenda (pipeline overview, technology deep dive, capital markets initiative/uplisting), logistics (date, time, location, webcast details), and provides contact information. This type of event, focused on presenting strategy and pipeline updates to investors, aligns best with an Investor Presentation (IP) or a general event announcement. Since it is an invitation to an event where presentations will be given, and the content focuses heavily on strategy and pipeline updates, 'Investor Presentation' (IP) is the most fitting category, as Capital Markets Days often serve as extended investor presentations. It is not a formal regulatory filing like 10-K or IR, nor is it a simple earnings release (ER).
2022-05-06 English
Nykode Therapeutics AS - Notice of Annual General Meeting
Capital/Financing Update Classification · 95% confidence The document is a formal 'Redegjørelse' (Statement/Report) prepared by an independent expert ('uavhengig sakkyndig') regarding the conversion of a private limited company (AS) to a public limited company (ASA) for Nykode Therapeutics AS. This process involves assessing assets and liabilities to ensure they cover the required share capital for an ASA, as mandated by Norwegian company law (aksjeloven § 2-6). This type of document, which details the results of an internal or regulatory assessment concerning the company's structure or financial standing, fits best under the 'Audit Report / Information' category, as it is a formal, expert-verified report on financial standing related to a structural change, distinct from a full annual report (10-K) or a quarterly report (IR). Keywords supporting this: 'Redegjørelse', 'uavhengig sakkyndig', 'aksjeloven § 2-6', 'eiendeler og forpliktelser', 'nettoverdi', 'BDO AS' (auditor). Although it is Norwegian, the function aligns with formal audit/assessment reports.
2022-05-05 Norwegian
Nykode Therapeutics AS - Notice of Annual General Meeting
AGM Information Classification · 98% confidence The document is explicitly titled 'Proposals from the Nomination Committee in Nykode Therapeutics AS to the Annual General Meeting to be held on May 12, 2022'. It details proposed changes to the Board of Directors (new members, stepping down members) and proposes remuneration structures for the Board and the Nomination Committee, all in preparation for the AGM. This content strongly aligns with materials presented or discussed during an Annual General Meeting, specifically focusing on board composition and related compensation, which falls under the scope of AGM materials.
2022-05-05 English
Nykode Therapeutics AS - Notice of Annual General Meeting
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2021' and contains comprehensive sections including a letter to shareholders, financial highlights, management review, corporate governance, and full financial statements (income statement, balance sheet, cash flows, notes, and auditor's report). It covers the full fiscal year 2021 and provides a detailed overview of the company's business, strategy, and financial performance, fitting the definition of a 10-K (Annual Report). FY 2021
2022-05-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.